This article first appeared on GuruFocus .
-
Operating Expenses:Company aims to reduce total operational expenses to approximately $6 million annually.
-
Transactions:Completed two transactions in the first half of 2026, including participation in an IPO for Ticketplus, which closed after the second quarter.
-
eXoZymes Stake:Holds 4.1 million shares plus warrants.
-
Paulex Bio Stake:Holds approximately 7.1 million shares plus warrants.
-
Public Ventures Ownership:100% ownership of the clearing platform.
-
PatentVest Ownership:100% ownership of the patent law platform.
Release Date: August 13, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
Positive Points
-
MDB Capital Holdings LLC ( NASDAQ:MDBH ) is focusing on monetizing its four core assets (Public Ventures, PatentVest, eXoZymes, and Paulex Bio) to reach key value inflection points, with a clear plan to avoid dilution for shareholders.
-
The company is actively pursuing partnerships or a sale of its Public Ventures clearing platform, with interest from multiple parties and a potential deal expected within the next quarter, which could unlock significant value.
-
PatentVest has pivoted to an AI-enabled ABS law firm model, positioning it as a leader in the future of patent law, with a financing round planned to spin it out as an independent entity, attracting external investors.
-
eXoZymes is nearing commercial inflection points, including potential strategic manufacturing partnerships and commercial deals, which could drive substantial valuation expansion similar to past successes.
-
Paulex Bio is close to filing for an IPO, with promising preclinical data on beta cell expansion for diabetes, potentially leading to a major value-creating event for MDBH.
-
MDBH is committed to operating with financial discipline, targeting $5-6 million in annual operational expenses, which can be offset by fees, ensuring sustainability without dilution.
-
The company has a strong track record of 17 IPOs over 29 years, with all trading at significant premiums post-IPO, and management remains confident in the potential for future value creation.
-
MDBH is leveraging its close to three decades of experience to actively help portfolio companies like eXoZymes and Paulex Bio with commercialization and investor outreach, enhancing their value.
-
The company is exploring nondilutive funding options for eXoZymes, such as spin-outs or strategic investments, to reduce capital needs and create value.
-
Management is actively engaging with investors through podcasts and conferences to communicate the company's story and the leverage embedded in its shares.
Negative Points
-
MDB Capital Holdings LLC ( NASDAQ:MDBH ) is operating in a challenging microcap market, with the sub-$200 million market cap sector being largely neglected by investors, leading to depressed stock prices.
-
The company's stock price is down from its IPO, and management acknowledges dissatisfaction with this performance, which may erode investor confidence.
-
The plan to scale new company launches from one every 18 months to three to five per year has been put on hold due to unfavorable market conditions, limiting growth opportunities.
-
The company's financial results are described as 'lumpy' due to the irregular nature of transactions, which can make it difficult for investors to predict performance.
-
eXoZymes' recent financing raised only $6 million, below expectations, highlighting challenges in raising capital in the current environment.
-
The microcap market's lack of institutional participation and fund flows is a significant headwind, as many small companies struggle to gain coverage and valuation expansion.
-
There is a risk that the anticipated value inflection points for portfolio companies may not materialize as expected, given the volatile nature of the sector.
-
The company's efforts to attract new investors are hampered by the asset class being out of favor, with conferences and podcasts having limited reach.
-
PatentVest's pivot to an AI-enabled law firm is a significant strategic shift that carries execution risks, and the success of the spin-out is uncertain.
-
The potential partnership or sale of Public Ventures is not guaranteed, and if it fails, the platform may remain underutilized, adding to operational costs.
Q & A Highlights
Q: Can you talk about how you are helping portfolio companies like eXoZymes and Paulex Bio recognize their full value and get their story out to investors? A: Christopher Marlett, CEO: We bring nearly three decades of experience to help manage these companies. For eXoZymes, we are actively helping secure commercial relationships and simplifying the complex science for investors. For Paulex, we are advising on strategic decisions like the best way to go public. Our focus is on connecting the dots for these small companies, getting them in front of people who can make a difference, and helping them overcome the "wall of doubt" that surrounds them. We are not a typical investment bank; we are interested in seeing the stocks go up, not just getting a transaction done.
Q: As a shareholder, what are you doing to get the MDB story out and attract new investors given the current stock price? A: Christopher Marlett, CEO: We are being consistent in our outreach, doing podcasts and attending conferences, though the microcap conference scene is currently unpopulated. We are talking to Family Office and RIA platforms. People love the concept of what we are doing intellectually, but money is currently flowing to large-cap names like NVIDIA. We just have to stay consistent, tell the story, and rely on our shareholders for feedback. We don't believe we have it all figured out and are open to bright ideas.
Q: How do you feel about HeartBeam right now, its technology, and where the company is at? A: Christopher Marlett, CEO: The technology can be completely transformative, as it can read ECG signals better than anyone with an ambulatory device. I am happy they have acknowledged that launching the product on their own was not the right approach. The right strategy is to partner with companies that have existing channels, as it is more capital-efficient and avoids dilution. This device needs to be everywhere, but they need to do partnership deals to get there. This new strategy extends their runway and could represent an unbelievable opportunity for investors who do their work.
Q: Regarding eXoZymes' recent financing, which raised around $6 million, can you characterize the challenges and where they are going? A: Christopher Marlett, CEO: The focus is on managing dilution and being capital efficient. They have huge asymmetric upside with an OpEx of around $10 million a year. We have discussed spinning out NCT as its own separately funded platform, which would be a value-creating event and lessen capital needs. Other molecules could also be used for strategic investments or spin-outs that are nondilutive. Once they hit a value inflection point with commercial deals, future financings will become less dilutive and easier to execute as people see the path to commercialization.
Q: Can you elaborate on the plan for Public Ventures and the self-clearing platform? A: Christopher Marlett, CEO: We built the self-clearing platform over five years on a lean budget, but we are not leveraging it enough with fewer new company launches. We are looking to partner it with a broader platform or potentially sell it. We are in discussions with four to five parties and have received letters of intent. We aim to wrap something up in the next quarter. This would allow us to focus on our core strength of launching big ideas while creating value from the platform we built.
Q: What is the new strategy for PatentVest, and why the pivot? A: Christopher Marlett, CEO: We realized our platform is perfectly positioned to pair with AI to build the law firm of the future. We are starting an ABS (Alternative Business Structure) law firm in Arizona, which allows us to own a law firm and bring in efficient business processes. This will attract great patent lawyers by offering a platform that provides unprecedented efficiency without taking money out of their pockets. We are executing a financing to spin PatentVest out as an independent entity, allowing outside investors to participate in its growth.
Q: What are the key upcoming catalysts for Paulex Bio? A: Christopher Marlett, CEO: Paulex is very close to filing its registration statement for an IPO, which we hope to see in the fourth quarter of this year. The drug has the potential to enable beta cell expansion, which could be a core differentiator for all GLP-1 platforms. We believe big pharma will have to take notice. We expect the core value-inflection data to start playing out in early 2027. This could be groundbreaking for patients and a massive value inflection point for Paulex and MDB.
Q: What is the company's financial strategy to avoid dilution and achieve sustainability? A: Christopher Marlett, CEO: Our plan is to operate on a lean platform of $5 million to $6 million a year, offset by fee income from transactions. By spinning out PatentVest and partnering off the clearing operations, we can reduce our operational expenses. This provides sustainability without dilution, allowing us to hold our positions and wait for key inflection points. We are not looking to raise more money or spend more, but to monetize and leverage the assets we have built.
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
